RDY250117P7500
- 0.00
- 0.000.00%
Dr. Reddy's Laboratories Newsroom
Nomura Upgrades Dr. Reddy's Laboratories to Buy From Neutral, Cuts Price Target to 1,500 Indian Rupees From 6,499 Indian Rupees
Dr Reddy's Labs Is Maintained at Overweight by Barclays
Dr Reddy's Laboratories Analyst Ratings
Barclays Maintains Dr. Reddy's Laboratories(RDY.US) With Buy Rating, Cuts Target Price to $17
Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,130 From INR1,120, Keeps at Underperform
Dr Reddy's Laboratories Analyst Ratings
BofA Securities Maintains Dr Reddy's Laboratories Ltd(RDY.US) With Buy Rating
Dr Reddy's Laboratories Analyst Ratings
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $81
Dr Reddy's Laboratories Analyst Ratings
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $70 From $67, Maintains Overweight Rating
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $70
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $66 From $69, Reiterates Overweight Rating
Barclays Maintains Overweight on Dr Reddy's Laboratories, Lowers Price Target to $66
Barclays Adjusts Dr. Reddy's Laboratories' Price Target to $69 From $68, Maintains Overweight Rating
Dr Reddy's Labs Is Maintained at Overweight by Barclays
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $69
Barclays Lowers Dr. Reddy's Laboratories' Price Target to $68 From $70, Maintains Overweight Rating
Dr Reddy's Labs Price Target Cut to $68.00/Share From $70.00 by Barclays
Dr Reddy's Labs Is Maintained at Overweight by Barclays